Table 2 Results of rifampicin susceptibility testing and rpoB genotyping

ST22- MRSA-IV (22)

Sporadic isolate (1)/t032 (1)

Cape Town, RSA⁵

≤ 0.016

498

GCG → GCT

-

554

CAT → CAC

-

599

AAT → AAC

-

ST36- MRSA-II (30)

F (1)/t021 (1)

Cape Town, RSA

≤ 0.016

474

AAC → AAT

-

498

GCG → GCT

-

502

GTA → GTG

-

518

ACA → ACG

-

ST5- MRSA-I (5)

C (1)/t045 (1)

Cape Town, RSA

≥ 256

481

C AT → T AT

H₄₈₁Y

498

GCG → GCT

-

630

AAT → AAC

-

658

GGT → GGA

-

ST612- MRSA-IV (8)

D (2), E (5), sporadic isolates (2)/t064 (3), t1443 (5), t1257 (1)

Cape Town, RSA

≥ 256

481

C AT → A AT

H₄₈₁N

498

GCG → GCT

-

512

CGT → CGC

-

527

ATT → ATG

I₅₂₇M

ST612- MRSA-IV (8)

ND⁶ (2)/t064 (2)

RSA (N83; N84)

≥ 256

481

C AT → A AT

H₄₈₁N

498

GCG → GCT

-

512

CGT → CGC

-

527

ATT → ATG

I₅₂₇M

ST612- MRSA-IV (8)

ND (1)/t064 (1)

Australia (04-17052)

≥ 256

481

C AT → A AT

H₄₈₁N

498

GCG → GCT

-

512

CGT → CGC

-

527

ATT → ATG

I₅₂₇M

ST612- MRSA-IV (8)

ND (1)/t7571 (1)

Australia (09-15534)

≥ 256

481

C AT → A AT

H₄₈₁N

498

GCG → GCT

-

512

CGT → CGC

-

527

ATT→ATG

I₅₂₇M

579

AA A→AG A

K₅₇₉R